SCHEMBL21751670

SCHEMBL21751670

N[C@@H](CCO)c1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 1/20 0.44
TSHR P16473 2/20 0.43
KCNA5 P22460 5/20 0.42
KCNE1 P15382 2/20 0.42
CYP2D6 P10635 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
CHRM2 P08172 1/20 0.41
SCN1A P35498 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN3A Q9NY46 1/20 0.41
KCNH2 Q12809 1/20 0.41
ALDH1A1 P00352 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22559174 1.00 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3TSHRKCNA5
SCHEMBL30867636 1.00 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3TSHRKCNA5
SCHEMBL10002427 0.86 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3TSHRKCNA5
SCHEMBL3388486 0.86 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3TSHRKCNA5
SCHEMBL1439087 0.86 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3TSHRKCNA5
SCHEMBL24099467 0.86 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3TSHRKCNA5
SCHEMBL3224199 0.86 HRH1 (0.45) SLC6A2SLC6A4SLC6A3TSHRKCNA5
Hydrochloric Acid SCHEMBL5846124 0.84 HRH1 (0.44) SLC6A2SLC6A4SLC6A3TSHRKCNA5
Hydrochloric Acid SCHEMBL28631671 0.84 HRH1 (0.44) SLC6A2SLC6A4SLC6A3TSHRKCNA5
Hydrochloric Acid SCHEMBL17497471 0.84 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3TSHRKCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025122956-A1 COMBINATION THERAPY VIVACE THERAPEUTICS, INC. (US) 2025-06-12 WO disclosed
WO-2025034563-A1 COMPOUNDS AND METHODS FOR TREATING CANCER VIVACE THERAPEUTICS, INC. (US) 2025-02-13 WO disclosed
EP-4110298-A1 HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) 2023-01-04 EP disclosed
EP-3877356-A1 BICYCLIC COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-09-15 EP disclosed
WO-2020041406-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. (US) 2020-02-27 WO disclosed